Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Last trade$3.40
Day change-$0.21 (-5.83%)
Day range$3.34 – $3.92
Volume2,086,737
Market cap$572M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$572.59M
Price / earnings
—
Price / book
3.43×
Price / sales
89.45×
EV / sales
86.27×
EV / EBITDA
-6.16×
Profitability
Earnings per share
-$0.50
Return on assets
-36.84%
Return on equity
-47.74%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.09×
Quick ratio
5.09×
Cash ratio
0.84×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$75.32M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ACRS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.48M
$1.63M
$2M
$1.3M
$3.3M
$1.78M
$1.46M
$9.21M
Cost of revenue
$189K
$218K
$395K
$532K
$538K
$515K
$506K
$705K
Gross profit
$1.29M
$1.41M
$1.6M
$763K
$2.76M
$1.26M
$949K
$8.51M
Selling, general and administrative
$6.04M
$6.05M
$6.74M
$5.58M
$4.87M
$5.39M
$6.14M
$4.95M
Research and development
$16.07M
$18.07M
$15.66M
$16.58M
$13.03M
$11.45M
$11.58M
$95.93M
Total operating expenses
$22.64M
$25.65M
$23.79M
$23.5M
$19.91M
$19.67M
$18.73M
$108.18M
Operating income
-$21.34M
-$24.24M
-$22.19M
-$22.73M
-$17.15M
-$18.41M
-$17.78M
-$99.68M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$18.51M
-$21.51M
-$19.82M
-$19.8M
-$14.61M
-$15.43M
-$15.09M
-$96.55M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$18.51M
-$21.51M
-$19.82M
-$19.8M
-$14.61M
-$15.43M
-$15.09M
-$96.55M
Net income attributable to common shareholders
-$18.51M
-$21.51M
-$19.82M
-$19.8M
-$14.61M
-$15.43M
-$15.09M
-$96.55M
EBITDA
-$21.24M
-$24.13M
-$22.09M
-$22.23M
-$17.04M
-$18.29M
-$17.66M
-$100.83M
Basic earnings per share
-$0.12
-$0.15
-$0.15
-$0.16
-$0.12
-$0.13
-$0.12
-$1.01
Diluted earnings per share
-$0.12
-$0.15
-$0.15
-$0.16
-$0.12
-$0.13
-$0.12
-$1.01
Recent news
Company coverage with links to the original publishers.
Aclaris Therapeutics announced positive Phase 1b results for its bispecific antibody ATI-052 targeting TSLP and IL-4Rα in atopic dermatitis and asthma. The drug demonstrated rapid and durable improvements in skin symptoms and itch in severe AD patients, with 78% achieving EASI-50 response. In asthma, a single dose produced rapid improvements in airway inflammation and lung function. The compound showed a favorable safety profile with no conjunctivitis observed. Aclaris plans to prioritize Phase 2b development in eosinophilic esophagitis (EoE) starting early 2027.
Aclaris Therapeutics announced that CEO Dr. Neal Walker will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 10, 2026. The clinical-stage biopharmaceutical company, which focuses on developing treatments for immuno-inflammatory diseases, will provide a live and archived webcast of the event on its website.
Aclaris Therapeutics announced that results from its Phase 2a trial of ATI-2138, an investigational oral covalent inhibitor of ITK and JAK3, will be presented as an ePoster at the 2026 AAD Annual Meeting in Denver. The poster will include previously unreported results from the open-label trial in patients with moderate-to-severe atopic dermatitis.
Aclaris Therapeutics announced the initiation of a Phase 1b proof-of-concept trial for ATI-052, a bispecific antibody targeting TSLP and IL-4Rα, in asthma patients. This follows the recent start of a similar trial in atopic dermatitis. The company expects to report top-line results from both trials in the second half of 2026 and plans to initiate a Phase 2b program shortly thereafter.
Aclaris Therapeutics will participate in the Piper Sandler 37th Annual Healthcare Conference in New York City on December 2, 2025, with CEO Dr. Neal Walker presenting a fireside chat.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.